Adamopoulos S, et al.99. Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, et al. Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure. Am J Cardiol 2006 1;98:102-6. PMID: 16784930 2006 |
L. ventricular dysfunction EF < 30% (46) |
Levosimendan 6 microg/kg attack 0.1 microg/kg/min continuously for 24h (23) |
Dobutamine 5microg/kg/min 24h (23) |
Death |
4 months |
Alvarez J, et al.1010. Alvarez J, Bouzada M, Fernández AL, Caruezo V, Taboada M, RodrÃguez J, et al. Ginesta [Hemodynamic effects of levosimendan compared with dobutamine in patients with low cardiac output after cardiac surgery]. Rev Esp Cardiol 2006;59:338-45. PMID: 16709386 2006 |
PO of heart surgery with low cardiac output (50) |
Levosimendan 12 microg/kg attack 0.2 microg/kg/min continuously for 24h (25) |
Dobutamine 7.5microg/kg/min 24h (25) |
Death |
24h |
Bonios MJ, et al.1111. Bonios MJ, Terrovitis JV, Drakos SG, Katsaros F, Pantsios C, Nanas SN, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 2012 6;159:225-9. PMID: 21481958 2012 |
Chronic heart failure EF < 30 resistant to the standard treatment NYHA 4 (42) |
Levosimendan 0.2 microg/kg/min weekly / 6 months (21) |
Dobutamine 10 microg/kg/min weekly / 6 months (21) |
Death |
6 months |
Domingues-Rodriguez A, et al.1212. Dominguez-Rodriguez A, Samimi-Fard S, Garcia-Gonzalez MJ, Abreu-Gonzalez P. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol 2008 18;128:214-7. PMID: 17643535 2008 |
Cardiogenic shock (AMI) after percutaneous intervention. EF < 30 (22) |
Levosimendan – 24 microg/kg attack – 0.1 microg/kg/min continuously for 24h (11) |
Dobutamine 5microg/kg/min 24h (11) |
Death |
24h |
Follath F, et al.1313. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002 20;360:196-202. PMID: 12133653 2002 |
Heart failure EF < 35 (203) |
Levosimendan – 24 microg/kg attack – 0.1 microg/kg/min continuously for 24h (100) |
Dobutamine 5microg/kg/min 24h (103) |
Death |
24h, 31d, 180d |
Levin RL, et al.1414. Levin RL, Degrange MA, Porcile R, Salvagio F, Blanco N, Botbol AL, et al. [The calcium sensitizer levosimendan gives superior results to dobutamine in postoperative low cardiac output syndrome]. Rev Esp Cardiol 2008;61:471-9. PMID: 18462650 2008 |
PO of revasc. Syndr. Low Cardiac Output (137) |
Levosimendan 10 microg/kg attack 0.1 microg/kg/min continuously for 24h (69) |
Dobutamine 5microg/kg/min 24h (68) |
Death |
30 days |
Mebazaa A, et al.1515. Mebazaa A, Nieminen MS, Filippatos GS, Cleland JG, Salon JE, Thakkar R, et al. Levosimendan vs. dobutamine: outcomes for acute heart failure patients on beta-blockers in SURVIVE. Eur J Heart Fail 2009;11:304-11. PMID: 19158152 2007 |
Acute heart failure EF < 30 |
Levosimendan 12 microg/kg attack 0.1 microg/kg/min continuously for 50min 0.2 microg/kg/min 23h (664) |
Dobutamine 5microg/kg/min 24h (663) |
Death |
31 d; 180 d |